Filtered By:
Cancer: Skin Cancer
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1104 results found since Jan 2013.
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
CONCLUSION: This triple combining in situ vaccine induced intensive antitumor responses, mediated effective systemic tumor control and survival benefit, and displayed impressive synergistic antitumor effect with checkpoint blockade therapy. These data preliminary confirmed the efficacy, feasibility and safety of the triple combining in situ vaccine, suggesting its great application potential as both monotherapy and a part of combined immunotherapeutic regimens in clinical scenario.PMID:37700338 | DOI:10.1186/s12967-023-04504-w
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Zhichen Sun Yanhong Chu Jie Xiao Yueling Yang Fanyan Meng Xinyue Wang Yanbing Dong Junmeng Zhu Yirong Wu Lanqun Qin Yaohua Ke Baorui Liu Qin Liu Source Type: research
Age-dependent modulation of gut microbiome in response to tumor immunomodulation
In this study, we sequentially treated young mice (~8 weeks) and old mice (>18 months) with bilateral melanoma using FUS and calreticulin nanoparticles (CRT-NP) to enhance immunogenic cell death. The combination of CRT-NP and FUS (CFUS) demonstrated greater efficacy in inducing regression of treated and untreated tumors in young mice compared to old mice. The diminished effectiveness in older mice was associated with significant differences in gut microbiome composition, characterized by alterations in bacterial species and splenic immune cells. Specifically, young mice exposed to CFUS exhibited higher abundance of Bact...
Source: Experimental Gerontology - August 12, 2023 Category: Geriatrics Authors: Akansha Singh Harshini Ashar Ashish Ranjan Source Type: research
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
CONCLUSIONS: The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial.TRIAL REGISTRATION NUMBER: NCT02301611.PMID:37536936 | DOI:10.1136/jitc-2023-006665
Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Elizabeth Lee Carpenter Spencer Van Decar Alexandra M Adams Anne E O'Shea Patrick McCarthy Robert Connor Chick Guy Travis Clifton Timothy Vreeland Franklin A Valdera Ankur Tiwari Diane Hale Phillip Kemp Bohan Annelies Hickerson Todd Smolinsky Katryna Thom Source Type: research
Liquid nitrogen frozen cells for chemotherapy drug delivery and vaccination of melanoma
CONCLUSION: In this work, we obtain the LNF cells with a simple procedure. The LNF cells not only provides a tumor cells-based multi-modal system for cancer therapy but inspires new insights into future development of individualized CVs strategies. This study processes live B16F10 cells by liquid nitrogen frozen to obtain LNF cells, which preserve cell integrity and homologous targeting ability. The LNF cells can load and deliver drug and can serve as tumor vaccine. Results demonstrated the LNF cells have effective prophylactic ability, and ideal anti-tumor ability with the loaded drug and adjuvant.PMID:37522925 | DOI:10.1...
Source: Cancer Control - July 31, 2023 Category: Cancer & Oncology Authors: Minliang Wu Yuai Xiao Jianguo Huang Yuchong Wang Yifan Zhang Jianguo Xu Haiying Dai Chuan Lv Yihui Hu Bingdi Chen Qingge Fu Wenjun Le Chunyu Xue Source Type: research
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis
MedComm (2020). 2023 Jul 18;4(4):e286. doi: 10.1002/mco2.286. eCollection 2023 Aug.ABSTRACTTumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines could promote a clinical benefit to advanced cancer patients is highly unknown. PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023. Random effects models were employed. Clinical benefit (objective response rate [ORR], disease control rate [DCR], 1-year/2-year progression-free survival [PFS], and overall survival [OS]) and safety (vaccine-related grade 3-5 adverse events [AEs]) were evaluated. Overall, 984 patients (32 trials) were e...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Tian-Yi Zhang Hang Xu Xiao-Nan Zheng Xing-Yu Xiong Shi-Yu Zhang Xian-Yanling Yi Jin Li Qiang Wei Jian-Zhong Ai Source Type: research
rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
CONCLUSION: The rWTC-MBTA vaccine demonstrated efficacy in multiple animal models through T-cell mediated cytotoxicity and has potential as a therapeutic option for preventing and treating tumor metastasis with minimal systemic toxicity.PMID:37434263 | DOI:10.1186/s13046-023-02744-8
Source: Cell Research - July 11, 2023 Category: Cytology Authors: Juan Ye Herui Wang Rogelio Medina Samik Chakraborty Mitchell Sun Alex Valenzuela Xueyu Sang Yaping Zhang Ondrej Uher Jan Zenka Karel Pacak Zhengping Zhuang Source Type: research
Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFN γ
Clin Immunol. 2023 Jul 3:109685. doi: 10.1016/j.clim.2023.109685. Online ahead of print.ABSTRACTInducing tumor-specific T cell responses and regulating suppressive tumor microenvironments have been a challenge for effective tumor therapy. CpG (ODN), the Toll-like receptor 9 agonist, has been widely used as adjuvants of cancer vaccines to induce T cell responses. We developed a novel adjuvant to improve the targeting of lymph nodes. CpG were modified with lipid and glycopolymers by the combination of photo-induced RAFT polymerization and click chemistry, and the novel adjuvant was termed as lipid-glycoadjuvant@AuNPs (LCpG)....
Source: Clinical Immunology - July 5, 2023 Category: Allergy & Immunology Authors: Xiaojing Xu Cheng Yi Tianyun Feng Youzhen Ge Mengjie Liu Cenhao Wu Hao Yu Xiang Chen Subash C B Gopinath Weidong Zhang Lixiang Zhao Jun Zou Source Type: research
